SB216763

For research use only.

Catalog No.S1075

64 publications

SB216763 Chemical Structure

CAS No. 280744-09-4

SB216763 is a potent and selective GSK-3 inhibitor with IC50 of 34.3 nM for GSK-3α and equally effective at inhibiting human GSK-3β. SB216763 activates autophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 162 In stock
EUR 144 In stock
EUR 265 In stock
EUR 855 In stock
EUR 1051 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's SB216763 has been cited by 64 publications

Purity & Quality Control

Choose Selective GSK-3 Inhibitors

Biological Activity

Description SB216763 is a potent and selective GSK-3 inhibitor with IC50 of 34.3 nM for GSK-3α and equally effective at inhibiting human GSK-3β. SB216763 activates autophagy.
Targets
GSK-3α [1]
(Cell-free assay)
GSK-3β [1]
(Cell-free assay)
34.3 nM ~34.3 nM
In vitro

SB 216763 displays similar potency for GSK-3β with 96% inhibition at 10 μM while exhibiting minimal activity against 24 other protein kinases including PKBα and PDK1 with IC50 of >10 μM. SB 216763 stimulates glycogen synthesis in human liver cells with EC50 of 3.6 μM, and induces dose-dependent transcription of a β-catenin-LEF/TCF regulated reporter gene in HEK293 cells with a maximum 2.5-fold induction at 5 μM. [1] SB 216763 protects the cerebellar granule neurones from apoptotic cell death induced by LY-294002 or potassium-deprivation in a concentration-dependent manner, with a maximal neuroprotection at 3 μM in contrast with the effect of lithium chloride at which 10 mM is required. SB 216763 at 3 μM also completely prevents death of chicken dorsal root ganglion sensory neurones induced by LY-294002 regardless of NGF. SB 216763 treatment at 5 μM markedly inhibits the GSK-3-dependent phosphorylation of neuronal-specific microtubule-associated protein tau in cerebellar granule neurones or recombinant tau in HEK293 cells, and induces increased levels of cytoplasmic β-catenin in both cells mimicking the effect of Wnt-mediated inhibition of GSK-3. [2] In pancreatic cancer cell lines including BXPC-3, MIA-PaCa2, PANC1, ASPC1, and CFPAC, SB 216763 treatment at 25-50 μM reduces cell viability in a dose-dependent manner, and leads to significant increase in apoptosis by 50% at 72 hours due to the specific down regulation of GSK-3β, while has no effect in HMEC or WI38 cell lines. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 M{DyZ2Z2dmO2aX;uJIF{e2G7 NFLuT2dIdHmlb3flckB{gW62aHHz[UBi[3Srdnn0fUBw\iCKRVuyPVMh[2WubIOsJIlvcGmkaYTpc44hd2ZiR2PLN{1j\XSjLDDFR|UxRTBwMt88US=> NH;wVWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkm0NVM{OSd-MUK5OFE{OzF:L3G+
HEK293 NX[zTmk4TnWwY4Tpc44h[XO|YYm= NFj0bllG\m[nY4TpeoUh[2:wY3XueJJifGmxbjDv[kBkd22yb4Xu[EBi\2GrboP0JIdtgWOxZ3XuJJN6dnSqYYPlJItqdmG|ZT2zJIlvKEiHS{K5N{Bk\WyuczygSWM2OD1yLkNOwG0> NVX4ephCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWxOFk3QDRpPkG1NVQ6Pjh2PD;hQi=>
MIAPaCa2 MnLnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkXiO|IhcHK| M13jd2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1KSVCjQ3GyJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVA:OjYQvF2= M3j5dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{O4N|U2Lz5zOUOzPFM2PTxxYU6=
ST14A NYDBfpgyTnWwY4Tpc44h[XO|YYm= MVO2JIhzew>? M1H4U2lvcGmkaYTpc44hd2ZiR2PLMVMu[mW2YT3t[YRq[XSnZDDXcpQhe2mpbnHsbY5oKGmwIHj1cYFvKFOWMUTBJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGGlY4XteYxifGmxbjDv[kBj\XSjLXPhd4VqdiCjcn;1coQhdnWlbHX1d{Bi\nSncjC2JIhzeyCkeTDtbYNzd3Olb4DpZ{BidmGueYPpdy=> MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODdyOEmzO{c,OjB5MEi5N|c9N2F-
neural precursor cells M1nl[GZ2dmO2aX;uJIF{e2G7 NXfIOWJzUW6qaXLpeIlwdiCxZjDu[ZVzd3OyaHXy[UBxem:uaX\ldoF1cW:wIH;mJI1wfXOnIH7leZJidCCycnXjeZJ{d3JiY3XscJMh[nliTWTUJIF{e2G7 NXLoTXJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0NVc3OzFpPkG3OFE4PjNzPD;hQi=>
ReNcell VM NV;ucIUzSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= Mn\oN{B2VQ>? MUG3NkBpenN? NHT3XI5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGLlUoNmdGxiVl2gZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjdDCzJJVOKGGodHXyJFczKGi{cx?= NIXxV249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEewPFk{Pyd-MkC3NFg6Ozd:L3G+
HepG2 MUnGeY5kfGmxbjDhd5NigQ>? MUGzOEB2VQ>? M2PteVEzKGi{cx?= M3;hTGlv[3KnYYPlJIlvKGeudXPvd4UhcW6lb4Lwc5JifGmxbjDpckBpfW2jbjDI[ZBIOiClZXzsd{BifCB|NDD1UUBi\nSncjCxNkBpenNiYomg[4x2[2:|ZTDhd5NigQ>? NVrTOGZYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OlcyPTBpPkK1OFY4OTVyPD;hQi=>
3T3L1 MYTGeY5kfGmxbjDhd5NigQ>? MkmxN|QhfU1? M33RWlEzKGi{cx?= MnrrTY5kemWjc3WgbY4h\2y3Y3;z[UBqdmOxcoDvdoF1cW:wIHnuJI1wfXOnIEPUN2wyKGOnbHzzJIF1KDN2IIXNJIFnfGW{IEGyJIhzeyCkeTDncJVkd3OnIHHzd4F6 NGfmbZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS2O|E2OCd-MkW0OlcyPTB:L3G+
HepG2 NV3ZRo5JTnWwY4Tpc44h[XO|YYm= MoHpN|QhfU1? MnHoNVIhcHK| NUSy[WdtUW6qaXLpeIlwdiCxZjDHV2s{[mW2YTDpckBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDyZZRqdyCxZjDwbI9{eGixconsZZRm\CCJUz;HV{BifCB|NDD1UUBi\nSncjCxNkBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ MmfoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NkexOVAoRjJ3NE[3NVUxRC:jPh?=
Sf9 Mn3wSpVv[3Srb36gZZN{[Xl? NYLj[GNFOzBibXnu NV\YOmkxUW6qaXLpeIlwdiCxZjDHV2s{[mW2YTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBU\jliY3XscJMhfXOrbnegS3MyKGG|IIP1ZpN1emG2ZTDhcoQhY2ejbX3hN|JeSVSSIHHmeIVzKDNyIH3pckBjgSC|Y3nubZRtdGG2aX;uJINwfW62aX7nMEBKSzVyPUCuNFM{QDkQvF2= MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human HDLM-2 cell MmLWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYLJcohq[mm2aX;uJI9nKGi3bXHuJGhFVE1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlA6QDRizszN Mn;sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human NCI-H1770 cell M{H3[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{PjfWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO|cxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwIFnDOVA:OC5{OUO5NkDPxE1? MnrCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human HOP-62 cell M4[2[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUnYelVpUW6qaXLpeIlwdiCxZjDoeY1idiCKT2CtOlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh3MkW2JO69VQ>? NIK2[2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human JAR cell NWruOHZtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUO2cXVwUW6qaXLpeIlwdiCxZjDoeY1idiCMQWKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlIyODR2IN88US=> NV\Ed|BCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human K5 cell Mom5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV2wbmdxUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6NCCLQ{WwQVEvPTN4OUig{txO M1\4WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human MV-4-11 cell NG\xN2RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX\ST29RUW6qaXLpeIlwdiCxZjDoeY1idiCPVj20MVEyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi54OU[4OUDPxE1? NGfnRow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human BT-549 cell MlrBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{jqWmlvcGmkaYTpc44hd2ZiaIXtZY4hSlRvNUS5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4zQTN5NjFOwG0> NWjGZ4NkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human LB2241-RCC cell M3rG[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M13xO2lvcGmkaYTpc44hd2ZiaIXtZY4hVEJ{MkSxMXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwNEK4O|Qh|ryP NF25Sng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human GAMG cell NEPj[lJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3zDOWlvcGmkaYTpc44hd2ZiaIXtZY4hT0GPRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uOlU1ODlizszN NYnTRVJiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human HMV-II cell NULuZ4lLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NG\LUHRKdmirYnn0bY9vKG:oIHj1cYFvKEiPVj3JTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPjd4MEeg{txO M3y3[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human RS4-11 cell NVzlZ2puT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYPJcohq[mm2aX;uJI9nKGi3bXHuJHJUPC1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuNlQyPDFizszN NHnE[WE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human NCI-H1993 cell Ml3QS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoDCTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG5PVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05NjN4NUO0JO69VQ>? Moi5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human IST-SL1 cell NEOwVm5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYfJcohq[mm2aX;uJI9nKGi3bXHuJGlUXC2VTEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25MlAzODRizszN NXvqbFR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human SK-OV-3 cell M13iSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYSwdlhiUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QS5zMECyJO69VQ>? NV;VNlNtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human ESS-1 cell NYnBTYdKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGjrcZJKdmirYnn0bY9vKG:oIHj1cYFvKEWVUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU42QTh5MjFOwG0> M{nLTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human G-361 cell Mne3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlnyTY5pcWKrdHnvckBw\iCqdX3hckBINTN4MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwMlE4QThizszN NYTxU|c2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human ALL-PO cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlnWTY5pcWKrdHnvckBw\iCqdX3hckBCVExvUF:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNE4{PDd5IN88US=> NX7WRVZ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human NB5 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGKwfotKdmirYnn0bY9vKG:oIHj1cYFvKE6ENTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGxMlIyPTdizszN M{jh[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human DU-145 cell M2LQUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXW0cohwUW6qaXLpeIlwdiCxZjDoeY1idiCGVT2xOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOS54NUO1JO69VQ>? NGT4fVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human NMC-G1 cell MnzMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1jEcGlvcGmkaYTpc44hd2ZiaIXtZY4hVk2FLVexJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvPzJ4NDFOwG0> M3riNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human RPMI-7951 cell Mn[0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NInncnFKdmirYnn0bY9vKG:oIHj1cYFvKFKSTVmtO|k2OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LjDJR|UxRTFzLke4OlQh|ryP MkjvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human NCI-H2009 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVHHZ4NSUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxODliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMz6yOFI4KM7:TR?= NHvwSI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human LoVo cell NHT6XFlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUHJcohq[mm2aX;uJI9nKGi3bXHuJGxwXm9iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMz6zO|cyKM7:TR?= M1K2XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human A2058 cell NX3n[GRwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4jvfmlvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xN{41PjlizszN NFLleY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human D-566MG cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2TD[2lvcGmkaYTpc44hd2ZiaIXtZY4hTC13Nk\NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE{Njl2OEGg{txO M{WwPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human QIMR-WIL cell MljXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml;qTY5pcWKrdHnvckBw\iCqdX3hckBSUU2ULWfJUEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE2NjZ|OUSg{txO NYf5R|dmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human S-117 cell MmK3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoPITY5pcWKrdHnvckBw\iCqdX3hckBUNTFzNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG2MlQxOjJizszN NGi3[HM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human YH-13 cell MofsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3viNmlvcGmkaYTpc44hd2ZiaIXtZY4hYUhvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOk43QDZ3IN88US=> M3PJ[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human IGROV-1 cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEjreXJKdmirYnn0bY9vKG:oIHj1cYFvKEmJUl;WMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPy5{MECxJO69VQ>? M1HWW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human BHT-101 cell MnrWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3;5eWlvcGmkaYTpc44hd2ZiaIXtZY4hSkiWLUGwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE4NjZyOUmg{txO NXK3W5N3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human MKN45 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NY\Hd|BsUW6qaXLpeIlwdiCxZjDoeY1idiCPS160OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE5NjRzMkig{txO MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human A498 cell NVzLcXM3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlPFTY5pcWKrdHnvckBw\iCqdX3hckBCPDl6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUmuOFU1QSEQvF2= NYXzTHJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human U-266 cell M1PO[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWPJcohq[mm2aX;uJI9nKGi3bXHuJHUuOjZ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkCuPFc6PyEQvF2= NIK4eJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human BFTC-905 cell MoTZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlK1TY5pcWKrdHnvckBw\iCqdX3hckBDTlSFLUmwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIyNjF6N{mg{txO NV\aXY5FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human BxPC-3 cell NX;UeI5DT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2fPUWlvcGmkaYTpc44hd2ZiaIXtZY4hSniSQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvOzV3NDFOwG0> NH;ZdZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human NCI-SNU-1 cell MnjUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3;yVmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLWPOWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjFwNUW1PEDPxE1? Mn3YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human SF539 cell M330TWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHLQ[ZZKdmirYnn0bY9vKG:oIHj1cYFvKFOINUO5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlIvODF7ODFOwG0> MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human VA-ES-BJ cell NYm0T5h[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUizbpR3UW6qaXLpeIlwdiCxZjDoeY1idiCYQT3FV{1DUiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJ{LkW3OlMh|ryP M2DEfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human HuO-3N1 cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUfJcohq[mm2aX;uJI9nKGi3bXHuJGh2Vy1|TkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNk43OTVzIN88US=> NXfTeWFIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human EM-2 cell M4LSVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVKzOHFMUW6qaXLpeIlwdiCxZjDoeY1idiCHTT2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlIvPjZ6OTFOwG0> M4\BWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human T98G cell NVTHO4ZwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYKyPIIyUW6qaXLpeIlwdiCxZjDoeY1idiCWOUjHJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlMvOzByOTFOwG0> NEPwNYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human SW1783 cell M1zzUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXHJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTd6MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKzMlUzPDNizszN MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human NKM-1 cell M2PpVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkfVTY5pcWKrdHnvckBw\iCqdX3hckBPU01vMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKzMlg2OTJizszN NV21W4t7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human KOSC-2 cell Mn\BS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlzETY5pcWKrdHnvckBw\iCqdX3hckBMV1OFLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yOE4yOjl{IN88US=> M1jDfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human SW48 cell M3[xcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3Ph[WlvcGmkaYTpc44hd2ZiaIXtZY4hW1d2ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK0MlYxPjdizszN M2HiR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human NCI-H28 cell MkXzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yOU4zOTB2IN88US=> NW\J[5d7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human 5637 cell NITISZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYO5NYZRUW6qaXLpeIlwdiCxZjDoeY1idiB3NkO3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlUvQDFzMTFOwG0> MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human NB69 cell NWi1c2VjT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYnJcohq[mm2aX;uJI9nKGi3bXHuJG5DPjliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Nj6xO|Y1KM7:TR?= NWjPWpN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human HT-29 cell M{eycmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1LVemlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yO{4yPzV{IN88US=> MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human PFSK-1 cell M2nLRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1nYe2lvcGmkaYTpc44hd2ZiaIXtZY4hWE[VSz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlcvPTl|IN88US=> M{jaXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human UACC-257 cell NFnHWpJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVzJcohq[mm2aX;uJI9nKGi3bXHuJHVCS0NvMkW3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlcvPzR|IN88US=> NYfvc4o2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human D-423MG cell M37FZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF\Yb2xKdmirYnn0bY9vKG:oIHj1cYFvKERvNEKzUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zPy57MUC2JO69VQ>? NGHVeVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human NH-12 cell NUPTfm5pT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHrHfWdKdmirYnn0bY9vKG:oIHj1cYFvKE6KLUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlgvPDB3OTFOwG0> M{jUZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human DEL cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnW1TY5pcWKrdHnvckBw\iCqdX3hckBFTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{OT6wOFc1KM7:TR?= M4PxNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human LS-513 cell NVzxT3FRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn3YTY5pcWKrdHnvckBw\iCqdX3hckBNWy13MUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zNE4yOzN2IN88US=> M17nWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human NBsusSR cell NWXm[|R3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWHJcohq[mm2aX;uJI9nKGi3bXHuJG5De3W|U2KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zNE42Pjd6IN88US=> NWHQS4pQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human BV-173 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGPyV3pKdmirYnn0bY9vKG:oIHj1cYFvKEKYLUG3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMxNjd4NEmg{txO NUjHXFY{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human A101D cell MnrCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2L1VWlvcGmkaYTpc44hd2ZiaIXtZY4hSTFyMVSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zNE46Pzh2IN88US=> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human LU-134-A cell NXzhVlE2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGezVJNKdmirYnn0bY9vKG:oIHj1cYFvKEyXLUGzOE1CKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzFwMEKzPEDPxE1? M4HQ[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human ES3 cell MlW5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3LUSGlvcGmkaYTpc44hd2ZiaIXtZY4hTVN|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{GuN|M4PiEQvF2= MkjvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human NY cell MkjQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3PvSGlvcGmkaYTpc44hd2ZiaIXtZY4hVlliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Mj6yPVY2KM7:TR?= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human NCI-H1975 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlH6TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG5O|Uh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Oi5|NUiyJO69VQ>? MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human A704 cell MkXJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmPzTY5pcWKrdHnvckBw\iCqdX3hckBCPzB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{SuNlA2QSEQvF2= M3fkNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human SK-MEL-24 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlPqTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytNlQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{PC5{NUKzJO69VQ>? MmrLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human SW1088 cell NYC0[pc1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmLVTY5pcWKrdHnvckBw\iCqdX3hckBUXzFyOEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zOE4{PDV{IN88US=> Ml7iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human SK-MEL-1 cell NUfQU285T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoD0TY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7LDDJR|UxRTN2LkexOEDPxE1? NIDKSog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human MOLT-4 cell Mk\RS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWTJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO2MlE1PjdizszN MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human T47D cell NHvPfGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3S3eGlvcGmkaYTpc44hd2ZiaIXtZY4hXDR5RDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO3MlE3PDdizszN NY\hSFVPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human SW1710 cell MkLiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF\qSIVKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM4NjN4MEig{txO M2f2WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human MKN7 cell M3HLcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF3MfI5KdmirYnn0bY9vKG:oIHj1cYFvKE2NTkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zPE4xQTB7IN88US=> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human CAL-72 cell MoT1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGLtTpBKdmirYnn0bY9vKG:oIHj1cYFvKEODTD23NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM5NjFzN{ig{txO MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human AGS cell NEfx[5FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4jGSmlvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{iuNlA{QSEQvF2= M4PjOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human BE-13 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWnlTnhGUW6qaXLpeIlwdiCxZjDoeY1idiCERT2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM5Njd5OEOg{txO MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human Calu-6 cell M1\3e2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn70TY5pcWKrdHnvckBw\iCqdX3hckBE[Wy3LU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zPU43QTZ2IN88US=> MlPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human CAL-27 cell M3rPTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MULJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS0MlAxPTRizszN MnL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human BB49-HNC cell NGfqUohIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1PCZmlvcGmkaYTpc44hd2ZiaIXtZY4hSkJ2OT3IUmMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01PC5yMke4JO69VQ>? NUjuTJBMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
c-Myb; 

PubMed: 21795403     


Jurkat, K562, and RPMI 8226 cells were treated with or without 5 or 10 μM SB216763 for 8 h, and cell lysates were analyzed by immunoblotting. 

pGSK-3β / GSK-3β / E2F1 / β-catenin ; 

PubMed: 28042322     


Inhibition of GSK3β increased LSH expression. U251 (A) and HS683 (B) with treatment of SB216763 with different concentration as indicated were examined for the expression of LSH, p-GSK3β, GSK3β, E2F1, β-catenin and GAPDH by Western analysis. U251 (C) and HS683 (D) with treatment of 10μM SB216763 with time as indicated were examined for the expression of LSH, p-GSK3β, GSK3β, E2F1, β-catenin and GAPDH by Western analysis.

21795403 28042322
Growth inhibition assay
Cell viability; 

PubMed: 24779365     


Cell viability of mouse embryonic stem cells after exposure to GSK3 inhibitors. (A) Cell viability of the mouse embryonic stem cell line ES-D3 after a three day treatment with different concentrations of BIO, SB-216763, CHIR-99021 and CHIR-98014. Cell viability was measured with the MTT assay. DMSO without inhibitors was used as vehicle control. Data are expressed as percentages normalized to the control condition without inhibitors. (B) Cell viability of the mouse embryonic stem cell line ES-CCE after a three day treatment with different concentrations of BIO, SB-216763, CHIR-99021 and CHIR-98014. Values are means ± SEM, n = 3-5. ANOVA plus Dunnett’s post hoc test. ** p ≤ 0.01, * p ≤ 0.05 compared to the control.

24779365
In vivo Administration of SB 216763 at 20 mg/kg significantly prevents lung inflammation and the subsequent fibrosis in bleomycin (BLM)-induced pulmonary inflammation and fibrosis model in mice by significantly blocking the production of inflammatory cytokines MCP-1 and TNF-α by macrophages, and significantly improves the survival of BLM-treated mice. SB 216763 treatment causes a significant reduction in BLM-induced alveolitis by inhibiting alveolar epithelial cell damage. [4]

Protocol

Kinase Assay:[1]
- Collapse

GSK-3 activity assay:

GSK-3 kinase activity is measured, in the presence of various concentrations of SB 216763, in a reaction mixture containing final concentrations of 1 nM human GSK-3α, 50 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM Mg-acetate, 7.5 mM β-mercaptoethanol, 5% (w/v) glycerol, 0.01% (w/v) Tween-20, 10% (v/v) DMSO, and 28 μM GS-2 peptide substrate. The GS-2 peptide sequence corresponds to a region of glycogen synthase that is phosphorylated by GSK-3. The assay is initiated by the addition of 0.34 μCi [33P]γ-ATP. The total ATP concentration is 10 μM. Following 30 minutes incubation at room temperature the assay is stopped by the addition of one third assay volume of 2.5% (v/v) H3PO4 containing 21 mM ATP. Samples are spotted onto P30 phosphocellulose mats and washed six times in 0.5% (v/v) H3PO4. The filter mats are sealed into sample bags containing Wallac betaplate scintillation fluid. 33P incorporation into the substrate peptide is determined by counting the mats in a Wallac microbeta scintillation counter.
Cell Research:[3]
- Collapse
  • Cell lines: BXPC-3, MIA-PaCa2, PANC1, ASPC1, and CFPAC cells
  • Concentrations: Dissolved in DMSO, final concentrations ~50 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are exposed to various concentrations of SB 216763 for 24, 48 and 72 hours. Relative cell viability is measured using the MTS assay. Apoptotic cells are determined by staining with Hoechst.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: C57BL/6N mice with lung inflammation and fibrosis induced by bleomycin (BLM)
  • Dosages: 20 mg/kg
  • Administration: Intravenously
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (61.95 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.22
Formula

C19H12N2O2Cl2

CAS No. 280744-09-4
Storage powder
in solvent
Synonyms N/A
Smiles CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=C(C=C(C=C4)Cl)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

GSK-3 Signaling Pathway Map

GSK-3 Inhibitors with Unique Features

Related GSK-3 Products

Tags: buy SB216763 | SB216763 supplier | purchase SB216763 | SB216763 cost | SB216763 manufacturer | order SB216763 | SB216763 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID